NextBio Facilitates Additional Search Capabilities on Elsevier Platform Through Launch of Two New Applications

CUPERTINO, Calif.--(EON: Enhanced Online News)--NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, announced the launch of two new applications on the Elsevier SciVerse platform. The new applications, reflecting the successful ongoing collaboration between NextBio and Elsevier, further demonstrate NextBio’s capabilities for searching for relevant text in all types of content at the document, section, paragraph and sentence level. SciVerse is an innovative platform that integrates Elsevier's key products and encourages the scientific community to collaborate on the development of customized search and discovery applications.

“We have invested in building a comprehensive suite of APIs to enable our partners and customers to build their own applications, as illustrated by the SearchAssist application.”

The two new applications include:

• SearchAssist: An application that leverages NextBio’s auto-complete API and provides auto-complete suggestions composed of terms gathered from diseases, compounds, drugs, anatomy, organisms, genes, biogroups, SNPs (over 18 million), author names (over 6 million) and other biological concepts. It leverages a number of open ontologies including MeSH, Snomed CT, PubChem, DrugBank, and Gene Ontology.
• Section Search application: An application that decomposes an article into eight sections: Title, Abstract, Introduction, Methods, Results, Discussion, Summary, and Captions. A user can search through one or more of these sections to retrieve articles of interest and further filter their results using faceted (Year, Journals, Authors, and Affiliations) navigation.

These new applications add to the three previous applications – Matching Sentences, Methods Search, and Prolific Authors – that NextBio launched on the Elsevier SciVerse platform in September 2010.

“This suite of NextBio applications on SciVerse demonstrates how NextBio technology and APIs can be leveraged to build a variety of useful applications,” said Satnam Alag, NextBio Vice President of Engineering. “They also effectively demonstrate NextBio's capabilities for searching for relevant text at multiple levels within all types of content, not just content within the life and health sciences.”

“The new applications furthermore show the power of our applications framework, by which technology companies and academic developers can leverage our APIs and our content to build new solutions that enhance the search and discovery experience of our users,” said Rafael Sidi, Vice President, Application Marketplace and Developer Network, Elsevier.

“NextBio’s expertise in text-based search, ontology management, and semantic enrichment of content also very nicely complements our company’s own unique data search and correlations engine,” said Saeid Akhtari, NextBio co-founder, President and Chief Executive Officer. “We have invested in building a comprehensive suite of APIs to enable our partners and customers to build their own applications, as illustrated by the SearchAssist application.”

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively. For more information about SciVerse please visit http://www.info.sciverse.com/.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About NextBio

NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio's platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. NextBio's unique 'correlation engine' pre-computes billions of significant connections among public and private data and enables researchers to intelligently mine it in real-time. NextBio helps organizations increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.

Today, NextBio is used by researchers at the world's top commercial and academic institutions. NextBio's enterprise solution has been deployed at Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, UCB, and Takeda, among many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.